Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Certain genetic factors may contribute to frontal fibrosing alopecia in Brazil.

This study describes a successful reconstructive A-T flap surgery on a 74-year-old male with a 35mm basal cell carcinoma on the scalp, resulting in a 50mm defect, with no complications and optimal functional and cosmetic outcomes reported.

This case report describes a 67-year-old woman with frontal fibrosing alopecia and her daughter with lichen planopilaris, noting identical HLA D types which suggest a phenotypical link between these conditions.

This letter to the editor describes a case of postcast hypertrichosis in a patient with frontal fibrosing alopecia and reports no new research findings.

In this study, fractional CO2 laser treatment for alopecia areata was found to significantly increase terminal hair and patient satisfaction compared to betamethasone valerate cream alone, highlighting its efficacy and safety both as a standalone and combined treatment.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

This study observed that frontal fibrosing alopecia is increasingly diagnosed in Italian Caucasian females, often showing premenopausal onset and eyebrow alopecia as an early sign.

Alopecia areata greatly affects the quality of life for children and their families.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

EFBL offers hidden incisions, faster recovery, and fewer risks, but may raise hairline and cost more.

This study reported that while both DLQI and HADS showed moderate correlations, only DLQI correlated with clinician-assessed disease severity in patients with alopecia.

In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.

This review explores current therapeutic options for frontal fibrosing alopecia, noting the use of finasteride, topical tacrolimus, hydroxychloroquine, and excimer laser in managing the condition, but reports no new clinical results.

This review examines the characteristics of frontal fibrosing alopecia in postmenopausal women, highlighting the importance of biopsy for early diagnosis and potential treatment to prevent disease progression.

This study observed that among a Moroccan population with frontal fibrosing alopecia, common comorbidities included lichen planus pigmentosus (36.8%), rosacea (28.9%), thyroid disorders (23.7%), and dyslipidemia (21.1%), highlighting potential relationships mediated by shared inflammatory or metabolic pathways.

This article reviews the use of superficial temporal artery island flaps for facial reconstruction and provides a systematic approach for managing composite facial defects, reporting no major complications in 72 patients.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

This study reported that while various treatments for frontal fibrosing alopecia showed limited effectiveness, dutasteride most effectively stabilized the condition among patients at Duke University.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

This study describes a system called FOLLYSIS©, which uses mathematics and image analysis to optimize Follicular Unit Extraction hair transplants, showing high accuracy in measuring donor area density and reducing donor site injury.

This study reported that a non-ablative fractional laser effectively improved visible hair growth and scalp appearance in both men and women with androgenetic alopecia, with a high success rate in identifying post-treatment improvements, and no adverse events were documented among the 132 patients evaluated.

This thesis reviews current therapeutic approaches for ARFID and provides preliminary insights into enhancing treatment and care in Australia, including an evaluation of a pilot dietetic-led cognitive-behavioral therapy intervention.

This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.

This study analyzed 24 Japanese cases of fibrosing alopecia in a pattern distribution and found a distinctive "parachute" hair loss pattern, emphasizing unique clinical characteristics potentially influenced by racial factors.

This study found that patients with alopecia areata had significantly higher serum MIF levels compared to healthy controls, which correlated with greater disease severity and duration.

This study found that men with frontal fibrosing alopecia were more likely to have facial papules, androgenetic alopecia, and body hair loss compared to women, with the average patient age being higher than in other series, potentially explaining these differences.

This study found that the SAFE System may improve follicular unit extraction by reducing follicle transection rates and broadening patient eligibility, with only minor adverse reactions reported.